CAR T-Cell Therapy: A Promising Approach for HER2+ Breast Cancer with Brain Metastases
A groundbreaking study offers hope for patients with a challenging form of breast cancer.
A phase 1 trial (NCT03696030) presented at the 2025 Society of Neuro-Oncology Annual Meeting revealed that CAR T-cell therapy targeting HER2-positive breast cancer with brain and/or leptomeningeal metastases demonstrated early safety and efficacy.
But here's the intriguing part: this therapy was specifically designed for a difficult-to-treat form of cancer. And the results are promising!
The study involved patients with HER2-positive breast cancer that had spread to the brain or leptomeningeal region, a particularly aggressive and hard-to-treat form of the disease. The researchers administered HER2-directed CAR T-cell therapy, a type of immunotherapy, directly into the cerebrospinal fluid (CSF) of these patients, with or without lymphodepletion (LD), a process that reduces immune cells to enhance the effectiveness of the therapy.
Safety and Efficacy Findings:
- The therapy was well-tolerated, with the most common side effects being mild to moderate headaches, nausea, vomiting, fever, fatigue, and muscle pain, typically lasting less than 48 hours after a dose.
- Two cases of potential immune effector cell-associated neurotoxicity syndrome (grade 1/2) were observed in patients treated with LD and CAR T-cell therapy, causing confusion and lethargy.
- In the LD plus CAR T-cell therapy group (n=13), two patients experienced dose-limiting toxicities (DLTs) in the form of severe headaches (grade 3), which halted the planned doses of CAR T cells.
- Stable disease (SD) was achieved in both treatment groups. In patients receiving CAR T-cell therapy alone (n=10), 44% achieved SD with a median duration of 56 days. In the LD plus CAR T-cell therapy group, 64% achieved SD with a similar median duration.
Key Takeaways:
- HER2-directed CAR T-cell therapy showed initial safety and efficacy in treating recurrent brain/leptomeningeal metastases from HER2+ breast cancer.
- LD did not significantly improve the durability of SD but increased toxicity.
- The study suggests that this therapy may provide a new treatment option for patients with limited choices due to the aggressive nature of their cancer.
Study Design and Patient Criteria:
This single-center study enrolled patients aged 18 or older with confirmed HER2-positive breast cancer and recurrent brain or leptomeningeal metastases after radiation or intrathecal chemotherapy. Patients had a good performance status (Karnofsky score of at least 70) and could have received various prior therapies. They were not on high-dose dexamethasone and had to discontinue systemic chemotherapy or endocrine therapy during the first three cycles of CAR T-cell therapy.
The CAR T-cell therapy was administered at three dose levels, with escalating doses in subsequent cycles. In the LD plus CAR T-cell therapy group, LD was achieved using cyclophosphamide and fludarabine.
Correlative Analyses and Case Study:
The study also included correlative analyses, which revealed that higher doses and the addition of LD led to increased persistence of HER2 CAR T cells in the CSF. In a case study, a patient with HER2-positive, hormone receptor-positive breast cancer with brain and leptomeningeal metastases showed increased CAR T-cell persistence after LD, and malignant cells were no longer detected after subsequent doses of CAR T-cell therapy.
Controversial Interpretation:
While the study's lead author, Dr. Jana Portnow, noted that LD increased toxicity, she also suggested that it might enhance the therapy's on-target activity. This interpretation could spark debate, as it implies a potential trade-off between safety and efficacy.
What do you think? Is this a promising approach for such a challenging cancer? Do the potential benefits outweigh the risks? Share your thoughts in the comments below!
